Clinical Trials
22 trialsNCT06378177 2026-05-19
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Lyvgen Biopharma Holdings Limited
Phase 2 Active not recruiting
NCT06618014 2026-05-15
NeoTOP
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06462222 2026-05-11
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
Guangzhou Medical University
Phase 1/2 Active not recruiting
NCT06679985 2026-04-13
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Active not recruiting
NCT04387084 2026-03-23
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT05707910 2026-03-09
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
West China Hospital
Phase 1 Active not recruiting
NCT05888402 2026-02-27
InTRist
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT05518045 2026-02-04
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Active not recruiting
NCT06771622 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Phase 1/2 Active not recruiting
NCT06984588 2026-01-30
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
TJ Biopharma Co., Ltd.
Phase 2/3 Active not recruiting
NCT06416696 2026-01-02
Toripalimab for High-risk Locally Advanced Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT06584435 2025-12-19
TUORA
Tianjin Medical University Second Hospital
Phase 2 Active not recruiting
NCT06293690 2025-12-18
Toripalimab Combined With SBRT for NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Active not recruiting
NCT05975307 2025-12-01
BCIRT-01
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05980481 2025-09-29
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
RemeGen Co., Ltd.
Phase 2/3 Active not recruiting
NCT07047001 2025-07-09
Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT05167071 2025-04-27
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 1 Active not recruiting
NCT04517214 2025-04-02
Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma
Fudan University
Phase 2 Active not recruiting
NCT05869227 2024-12-30
Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT06717464 2024-12-05
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Active not recruiting
NCT04418154 2024-05-21
NeoTENNIS
Fudan University
Phase 2 Active not recruiting
NCT04304248 2021-05-06
NeoTAP01
Sun Yat-sen University
Phase 2 Active not recruiting